Flavonoids use in glioblastoma multiforme experimental models

Glioblastoma Multiforme (GBM) represents tumors that develop in the Central Nervous System (CNS) with the highest malignancy, incidence and prevalence. Flavonoid therapy has been gaining strength as an alternative adjuvant that counteracts the appearance and development of various cancers, including GBM. The objective of this review is to analyze the use of flavonoids in GBM therapy in a ten-year window (2013-2023). Fifty-one articles were reviewed, including original articles and bibliographic reviews. Flavonoids have been tested in different GBM in vitro models, decreasing proliferation and angiogenesis, activating signaling pathways and redirecting cell activity to alternative pathways that promote apoptosis and cell repair.